U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C53H90O22
Molecular Weight 1079.2685
Optical Activity UNSPECIFIED
Defined Stereocenters 29 / 29
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GINSENOSIDE RC

SMILES

CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2O[C@@H](CO)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]3CC[C@]4(C)[C@@H]3[C@H](O)C[C@@H]5[C@@]6(C)CC[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)C(C)(C)[C@@H]6CC[C@@]45C

InChI

InChIKey=JDCPEKQWFDWQLI-LUQKBWBOSA-N
InChI=1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-68-45-41(65)36(60)28(21-56)69-45)24-11-16-52(7)33(24)25(57)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)35(59)27(20-55)71-48)74-46-42(66)38(62)34(58)26(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28-,29+,30-,31+,32-,33-,34+,35+,36-,37+,38-,39-,40-,41+,42+,43+,44+,45+,46-,47-,48-,50-,51+,52+,53-/m0/s1

HIDE SMILES / InChI

Molecular Formula C53H90O22
Molecular Weight 1079.2685
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 29 / 29
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Ginsenoside Rc is a triterpene saponin originally found in species of Panax that exhibits antioxidative, anti-aging, antinociceptive, and anti-diabetic activities. Ginsenoside Rc inhibits phosphorylation of Foxo1, inhibits AMPK, activates PI3K/Akt signaling, and increases levels of catalase, decreasing oxidative stress. Ginsenoside Rc also induces antinociception in animal models of writhing and formalin-induced pain, potentially through activity on transient receptor potential vanilloid 1 (TRPV1) channels. In other animal models, ginsenoside Rc activates AMPK and p38 MAPK, increasing glucose uptake. Additionally, this compound increases the life span of Caenorhabditis elegans. Ginsenoside Rc has being shown to attenuate inflammatory symptoms in CIA, EtOH/HCl-mediated gastritis, and LPS/D-galactosamine (D-GalN)-triggered hepatitis without altering toxicological parameters, and without inducing gastric irritation. These anti-inflammatory effects were accompanied by the suppression of TNF-a and IL-6 production and the induction of anti-inflammatory cytokine IL-10 in mice with CIA. Ginsenoside Rc also attenuated the increased levels of luciferase activity by IRF-3 and AP-1, reduced TBK1, IRF-3, and ATF2 phosphorylation in the joint and liver tissues of mice with hepatitis. Ginsenoside Rc may be a major component of Korean Red Ginseng, marketed in Korea, with useful anti-inflammatory properties due to its suppression of IRF-3 and AP-1 pathways. Korean ginseng (Panax ginseng Meyer, Araliaceae) is traditionally used as an important herbal medicine in Far East Asia. Korean Red Ginseng is possibly effective for:

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
KRG extract contained 1.80mg/g Ginsenoside Rc, as well as ginsenoside-Rb1: 4.26mg/g, -B2: 1.71 mg/g, -Rb2: 1.62mg/g, -Rd: 0.29mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules (500 mg/dose) were taken daily for 12 weeks
Route of Administration: Oral
In Vitro Use Guide
Ginsenoside Rc inhibits MMP-13 expression in IL-1β-treated SW1353 cells at non-cytotoxic concentration (30 uM).
Substance Class Chemical
Record UNII
0K83B0L786
Record Status Validated (UNII)
Record Version